Selank

Selank is a linear 7-residue peptide built around the tuftsin tetrapeptide (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension at the C-terminus that provides resistance to aminopeptidase and carboxypeptidase cleavage. The molecule's interaction profile in the literature spans neuroimmunomodulator activity, GABAergic-system intersection in cortical-tissue assays, and BDNF-expression modulation in rodent-brain investigations. Pharmacokinetic descriptors documented in published animal-model studies include rapid absorption following intranasal paradigms and short systemic plasma residence under standard parenteral routes. No single high-affinity receptor has been definitively established for Selank in the literature; current published work frames its activity through composite engagement with neuroimmunomodulatory pathways. All activity descriptors here are framed as documented in published research. Structural confirmation is established by mass spectrometry and HPLC-validated purity on each Certificate of Analysis.

Experimental domains documented in the published literature include neuroimmunomodulator-pathway investigations, GABA-system intersection studies in cortical-tissue preparations, BDNF and other neurotrophic-factor expression analysis in rodent-brain assays, anxiety-related behavioral paradigms in animal models (rodent open-field and elevated-plus-maze designs), and structure-activity work probing the role of the Pro-Gly-Pro extension in conferring proteolytic stability. Investigators have also characterized Selank in comparative studies alongside the parent tuftsin tetrapeptide to dissect contributions of the C-terminal motif to in-vivo stability. Use in laboratory research extends to neuropeptide-pharmacology paradigms where the molecule serves as a probe for stabilized-tuftsin signaling. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C33H57N11O9 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.